HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Market News: Baze Patents ‘Recommendation Engine,' Built Brands Revamps, Expands Capacity

Executive Summary

Leafreport found 54% of 22 beverages contained less CBD than labeled; Built Brands rebrands protein, energy lineup with bigger facility to boost production; Baze Labs’ personalized nutrition “recommendation engine” patented; TruTrace blockchain platform for sanitizer; and Coffeeberry extract GRAS cleared by FDA.

You may also be interested in...



Digital Citizens Study Finds Many CBD Products Are Placebos And Most Are Inaccurately Labeled

Digital Citizens Alliance found an average 30% discrepancy between labeled and actual CBD amounts in nearly 60 products. The group says more than half the products tested contained CBD levels 20% higher or lower than labeled, which is particularly problematic since nearly half US consumers use the products as alternatives to Rx drugs.

Bragg Live Wants Consumers To Know Efficacy Differs Among Apple Cider Vinegar Formats

Bragg Live says its survey highlights misconceptions consumers have concerning health benefits and efficacy of different delivery formats of apple cider vinegar.

Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims

NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.

Topics

UsernamePublicRestriction

Register

RS150392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel